Genetically-modified pig mesenchymal stromal cells: Xenoantigenicity and effect on human T-cell xenoresponses

Xenotransplantation

Volumn 18, Issue 3, 2011, Pages 183-195

  Ezzelarab, Mohamed ^a   Ezzelarab, Corin ^a   Wilhite, Tyler ^a   Kumar, Goutham ^a   Hara, Hidetaka ^a   Ayares, David ^b   Cooper, David K C ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b REVIVICOR INC   (United States)

Author keywords

1,3 galactosyltransferase gene knockout; cell xenotransplantation; islet transplantation; mesenchymal stromal cells; pig; T cells

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; B7 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 2; LEUKOCYTE ANTIGEN; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; SWINE LEUKOCYTE ANTIGEN CLASS II; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BABOON; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MODIFICATION; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMAL CELL; MESENCHYME CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STROMA CELL; SWINE; T LYMPHOCYTE; UPREGULATION; WILD TYPE; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD46; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELL DIFFERENTIATION; CELLS, CULTURED; ENDOTHELIAL CELLS; GALACTOSYLTRANSFERASES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULINS; INTERFERON-GAMMA; INTERLEUKIN-2; MESENCHYMAL STEM CELLS; PAPIO; STROMAL CELLS; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959715815     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2011.00635.x     Document Type: Article

References (38)

1. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH,. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008; 57: 1759.
2. Sordi V,. Mesenchymal stem cell homing capacity. Transplantation 2009; 87 (9 Suppl.): S42.
3. Solari MG, Srinivasan S, Boumaza I, et al., Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun 2009; 32: 116.
4. Boumaza I, Srinivasan S, Witt WT, et al., Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 2009; 32: 33.
5. Brusko TM,. Mesenchymal stem cells: a potential border patrol for transplanted islets? Diabetes 2009; 58: 1728.
6. Van Der Windt DJ, Bottino R, Casu A, et al., Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009; 9: 2716.
7. Hering BJ, Wijkstrom M, Graham ML, et al., Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12: 301.
8. Cardona K, Korbutt GS, Milas Z, et al., Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12: 304.
9. Rood PP, Bottino R, Balamurugan AN, et al., Reduction of early graft loss after intraportal porcine islet transplantation in monkeys. Transplantation 2007; 83: 202.
10. Dufrane D, Goebbels RM, Saliez A, Guiot Y, Gianello P,. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation 2006; 81: 1345.
11. Davani B, Ikonomou L, Raaka BM, et al., Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells 2007; 25: 3215.
12. Henriksson HB, Svanvik T, Jonsson M, et al., Transplantation of human mesenchymal stems cells into intervertebral discs in a xenogeneic porcine model. Spine (Phila Pa 1976) 2009; 34: 141.
13. Shabbir A, Zisa D, Leiker M, Johnston C, Lin H, Lee T,. Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation 2009; 87: 1275.
14. Poncelet AJ, Denis D, Gianello P,. Cellular xenotransplantation. Curr Opin Organ Transplant 2009; 14: 168.
15. Dai Y, Vaught TD, Boone J, et al., Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. Nat Biotechnol 2002; 20: 251.
16. Phelps CJ, Koike C, Vaught TD, et al., Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411.
17. Hara H, Long C, Lin YJ, et al., In vitro investigation of pig cells for resistance to human antibody-mediated rejection. Transpl Int 2008; 21: 1163.
18. Lin YJ, Hara H, Tai HC, et al., Suppressive efficacy and proliferative capacity of human regulatory T cells in allogeneic and xenogeneic responses. Transplantation 2008; 86: 1452.
19. Ezzelarab M, Welchons D, Torres C, et al., Atorvastatin down-regulates the primate cellular response to porcine aortic endothelial cells in vitro. Transplantation 2008; 86: 733.
20. Rogers NJ, Jackson IM, Jordan WJ, Hawadle MA, Dorling A, Lechler RI,. Cross-species costimulation: relative contributions of CD80, CD86, and CD40. Transplantation 2003; 75: 2068.
21. Longhi MP, Harris CL, Morgan BP, Gallimore A,. Holding T cells in check-a new role for complement regulators? Trends Immunol 2006; 27: 102.
22. Le Blanc K, Rasmusson I, Sundberg B, et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439.
23. Le Blanc K, Frassoni F, Ball L, et al., Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579.
24. Bartmann C, Rohde E, Schallmoser K, et al., Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007; 47: 1426.
25. Stenderup K, Justesen J, Clausen C, Kassem M,. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003; 33: 919.
26. Wagner W, Horn P, Castoldi M, et al., Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 2008; 3: e2213.
27. Tolar J, Nauta AJ, Osborn MJ, et al., Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25: 371.
28. Li Q, Hisha H, Takaki T, et al., Transformation potential of bone marrow stromal cells into undifferentiated high-grade pleomorphic sarcoma. J Cancer Res Clin Oncol 2010; 136: 829.
29. Rosland GV, Svendsen A, Torsvik A, et al., Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009; 69: 5331.
30. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM,. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 2010; 5: e10088.
31. Ezzelarab M, Ayares D, Cooper DK,. The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantation. Xenotransplantation 2010; 17: 3.
32. Erices AA, Allers CI, Conget PA, Rojas CV, Minguell JJ,. Human cord blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion. Cell Transplant 2003; 12: 555.
33. Phelps CJ, Ball SF, Vaught TD, et al., Production and characterization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation 2009; 16: 477.
34. Ito T, Itakura S, Todorov I, et al., Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation 2010; 89: 1438.
35. Madec AM, Mallone R, Afonso G, et al., Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52: 1391.
36. Polchert D, Sobinsky J, Douglas G, et al., IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745.
37. Ren G, Su J, Zhang L, et al., Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954.
38. Augello A, Tasso R, Negrini SM, et al., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482.